Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Metabolife targets men

This article was originally published in The Tan Sheet

Executive Summary

Ads featuring new Metabolife for Men carry theme "women aren't the only ones who want to lose weight," Metabolife International says. San Diego-based firm will continue ad strategy of in-store promotions, working with radio station DJs, as well as tagging product onto ads for overall Metabolife line. Men's offering, on shelves now, is similar to flagship Metabolife 356, with addition of lycopene for prostate health, HMB, ZMA mineral blend. Also, ephedra-free Metabolife Evening Formula liquid complements 356 as part of overall weight-loss program. Combination "will raise the body's metabolism, burn fat, promote lean muscle, promote energy, reduce appetite," Metabolife claims...

You may also be interested in...



Boston Scientific Pays More Than $1Bn For Lumenis’ Surgical Laser Business

Lumenis’ surgical business includes the MOSES laser system for minimally invasive urology surgery which will complement Boston Scientific’s LithoVue ureteroscope.

Finance Watch: Eleven Companies Reveal $1.45bn In $100m-Plus VC Deals

Private Company Edition: Clover’s $230m financing was the largest of recent mega-rounds. Century Therapeutics ($160m), Vividion ($135m) and eGenesis ($125m) also raised big rounds and investors Foresite Capital ($969m), Sofinnova Partners ($540m) and OMX Ventures ($150m) raised new VC funds. 

Takeda Takes Back Dravet, Lennox-Gastaut Candidate From Ovid

Revising the two companies’ 2017 epilepsy collaboration, Takeda will take over Phase III development and commercialization of soticlestat. Ovid gets $196m up front, and it can shift focus.

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel